ArticlemedRxiv : the preprint server for health sciences2026
An AI Model Identifies Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients from TAILORx, a Phase 3 Randomized Clinical Trial.
Nancy Chan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.